Fosun Pharma Announces First Nine Months Financial Results for 2012
Strong Performance with High Growth in Pharmaceutical Manufacturing Segment
Third Quarter Net Profit Increased 94.9% Compared to the Same Period Last Year
(31 Oct 2012, Hong Kong) Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or the “Company” and, together with its subsidiaries, the “Group”, Shanghai Stock Exchange: 600196; Hong Kong Stock Exchange: 2196), a leading healthcare company in the People’s Republic of China, announced its financial results for the nine months ended 30 September 2012 (the “reporting period”). According to unaudited financial report prepared in accordance with the Accounting Standards of the People's Republic of China, within the reporting period, the Company’s operating income was RMB5,388 million, representing an increase of 16.3% as compared to the same period last year. The net profit attributed to shareholders increased to RMB1,093 million within the reporting period. The Company’s third quarter 2012 net profit was up to RMB391 million with an increase of 94.9% compared to the same period last year, which was the third consecutive quarter of net profit growth. The rapid growth was a result of the continued core product sales growth in therapeutic area of metabolism, digestive tract, cardiovascular, central nervous system, blood system and anti-infection, as well as the contribution of the stable growth of Sinopharm Group.
Fosun Pharma successfully launched its IPO (Initial Public Offering) on the Main Board of the Stock Exchange of Hong Kong on 30 Oct 2012 and brought in various international institutional investors, such as sovereign wealth funds, international long-term funds, insurance institutions and Asian and European private banking customers. The Company’s global offering with HK$3,764 million net proceeds has become the world’s second largest IPO in the pharmaceutical industry since 2012. The raised funds will be primarily used in main business segments, especially in the mergers and acquisitions of pharmaceutical business and in the constructions of a research and development platform.
Chairman and Executive Director of Fosun Pharma, Mr. Chen Qiyu states: “As a leading listed company in Chinese pharmaceutical industry with operations strategically covering several important segments of the healthcare industry value-chain, Fosun Pharma’s outstanding performance in the first nine months of 2012 has proved once again its ability to grasp market opportunities, actively optimize the existing business, continuously invest in innovative research and development, and increase market shares in pharmaceuticals and other business segments in the Chinese market. After launched its IPO on the Main Board of the Stock Exchange of Hong Kong, the Company will continue to invest in innovative research and development. We will also pursue potential acquisitions of international enterprises with competitive advantages or high growth potential in its China business and the pharmaceutical enterprises that possess unique product lines, R&D abilities and sales network in the international market. Through all these efforts, Fosun Pharma will further strengthen its leading position in the market and continues to create value and share the Company’s developments with its shareholders.”
About Fosun Pharma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Shanghai Stock Exchange: 600196; Hong Kong Stock Exchange: 2196), was established in 1994 and listed on the Shanghai Stock Exchange in August 1998 and on the Hong Kong Stock Exchange in October 2012. It is a leading listed company in Chinese pharmaceutical industry. Fosun Pharma, specializing in modern biopharmaceutical and healthcare industry, has captured great opportunities of the rapidly developing China healthcare industry and the globalization of Chinese healthcare companies. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value chain, including pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research & development and manufacturing. As one of the largest healthcare companies in China, Fosun Pharma enjoys a competitive advantage in innovative research & development, marketing, integration and M&A, as well as human resources. Fosun Pharma is the forefront of listed pharmaceutical companies in China, in terms of sales revenue, net assets, net profit and the market value of shares. For more information, please visit www.fosunpharma.com
Third Quarter Net Profit Increased 94.9% Compared to the Same Period Last Year
(31 Oct 2012, Hong Kong) Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or the “Company” and, together with its subsidiaries, the “Group”, Shanghai Stock Exchange: 600196; Hong Kong Stock Exchange: 2196), a leading healthcare company in the People’s Republic of China, announced its financial results for the nine months ended 30 September 2012 (the “reporting period”). According to unaudited financial report prepared in accordance with the Accounting Standards of the People's Republic of China, within the reporting period, the Company’s operating income was RMB5,388 million, representing an increase of 16.3% as compared to the same period last year. The net profit attributed to shareholders increased to RMB1,093 million within the reporting period. The Company’s third quarter 2012 net profit was up to RMB391 million with an increase of 94.9% compared to the same period last year, which was the third consecutive quarter of net profit growth. The rapid growth was a result of the continued core product sales growth in therapeutic area of metabolism, digestive tract, cardiovascular, central nervous system, blood system and anti-infection, as well as the contribution of the stable growth of Sinopharm Group.
Fosun Pharma successfully launched its IPO (Initial Public Offering) on the Main Board of the Stock Exchange of Hong Kong on 30 Oct 2012 and brought in various international institutional investors, such as sovereign wealth funds, international long-term funds, insurance institutions and Asian and European private banking customers. The Company’s global offering with HK$3,764 million net proceeds has become the world’s second largest IPO in the pharmaceutical industry since 2012. The raised funds will be primarily used in main business segments, especially in the mergers and acquisitions of pharmaceutical business and in the constructions of a research and development platform.
Chairman and Executive Director of Fosun Pharma, Mr. Chen Qiyu states: “As a leading listed company in Chinese pharmaceutical industry with operations strategically covering several important segments of the healthcare industry value-chain, Fosun Pharma’s outstanding performance in the first nine months of 2012 has proved once again its ability to grasp market opportunities, actively optimize the existing business, continuously invest in innovative research and development, and increase market shares in pharmaceuticals and other business segments in the Chinese market. After launched its IPO on the Main Board of the Stock Exchange of Hong Kong, the Company will continue to invest in innovative research and development. We will also pursue potential acquisitions of international enterprises with competitive advantages or high growth potential in its China business and the pharmaceutical enterprises that possess unique product lines, R&D abilities and sales network in the international market. Through all these efforts, Fosun Pharma will further strengthen its leading position in the market and continues to create value and share the Company’s developments with its shareholders.”
About Fosun Pharma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Shanghai Stock Exchange: 600196; Hong Kong Stock Exchange: 2196), was established in 1994 and listed on the Shanghai Stock Exchange in August 1998 and on the Hong Kong Stock Exchange in October 2012. It is a leading listed company in Chinese pharmaceutical industry. Fosun Pharma, specializing in modern biopharmaceutical and healthcare industry, has captured great opportunities of the rapidly developing China healthcare industry and the globalization of Chinese healthcare companies. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value chain, including pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research & development and manufacturing. As one of the largest healthcare companies in China, Fosun Pharma enjoys a competitive advantage in innovative research & development, marketing, integration and M&A, as well as human resources. Fosun Pharma is the forefront of listed pharmaceutical companies in China, in terms of sales revenue, net assets, net profit and the market value of shares. For more information, please visit www.fosunpharma.com